Literature DB >> 16574954

Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes.

Kiyoyuki Ogata1, Yoshifumi Kishikawa, Chikako Satoh, Hideto Tamura, Kazuo Dan, Akio Hayashi.   

Abstract

The diagnosis of myelodysplastic syndromes (MDS) without an increase in blasts and ringed sideroblasts (low-grade MDS without ringed sideroblasts [LGw/oRS]) may be problematic because dysplastic features are not specific to MDS and approximately 50% of patients with LGw/oRS lack chromosomal aberrations. Here, we report the usefulness of flow cytometric characteristics of CD34(+) cells for LGw/oRS diagnosis. Bone marrow cells from LGw/oRS patients and controls (eg, cytopenic individuals without MDS) were analyzed using 4-color flow cytometry (FCM). We objectively determined reference ranges of 13 parameters related to CD34(+) cells with data from controls. In LGw/oRS patients, various abnormalities of CD34(+) cells-eg, decrease in CD34(+) B-cell precursors, aberrant expression or overexpression of various antigens on CD34(+) myeloblasts-were observed. We constructed a reproducible, flow cytometric scoring system for LGw/oRS diagnosis. High scores were observed in 16 of 27 LGw/oRS patients, regardless of the presence or absence of chromosomal aberrations, but not in any of the 90 controls. Among LGw/oRS patients with chromosomal aberrations, patients with trisomy 8 or del20(q) had low FCM scores (P = .002). As a result, most LGw/oRS patients were identified based on high FCM score, chromosomal aberration, or both.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574954     DOI: 10.1182/blood-2005-12-4916

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.

Authors:  Alex F Sandes; Mihoko Yamamoto; Sergio Matarraz; Maria de Lourdes L F Chauffaille; Sandra Quijano; Antonio López; Tsutomu Oguro; Eliza Y S Kimura; Alberto Orfao
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Authors:  Matteo G Della Porta; Cristina Picone; Cristiana Pascutto; Luca Malcovati; Hideto Tamura; Hiroshi Handa; Magdalena Czader; Sylvie Freeman; Paresh Vyas; Anna Porwit; Leonie Saft; Theresia M Westers; Canan Alhan; Claudia Cali; Arjan A van de Loosdrecht; Kiyoyuki Ogata
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.

Authors:  Marshall A Lichtman
Journal:  Oncologist       Date:  2013-08-27

4.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

5.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Authors:  Peter L Greenberg; Zhuoxin Sun; Kenneth B Miller; John M Bennett; Martin S Tallman; Gordon Dewald; Elisabeth Paietta; Richard van der Jagt; Jessie Houston; Mary L Thomas; David Cella; Jacob M Rowe
Journal:  Blood       Date:  2009-06-29       Impact factor: 22.113

6.  Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.

Authors:  Tim H-P Chen; Amal Kambal; Kilannin Krysiak; Mark A Walshauser; Gagan Raju; Justin F Tibbitts; Matthew J Walter
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

Review 7.  Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Authors:  Anna Porwit
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

8.  Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission.

Authors:  Sung-Chao Chu; Tso-Fu Wang; Yu-Chieh Su; Ruey-Ho Kao; Yi-Feng Wu; Dian-Kun Li; Szu-Chin Li; Chi-Cheng Li; Denise A Wells; Michael R Loken
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

9.  Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.

Authors:  Anna M Aalbers; Marry M van den Heuvel-Eibrink; Irith Baumann; Michael Dworzak; Henrik Hasle; Franco Locatelli; Barbara De Moerloose; Markus Schmugge; Ester Mejstrikova; Michaela Nováková; Marco Zecca; C Michel Zwaan; Jeroen G Te Marvelde; Anton W Langerak; Jacques J M van Dongen; Rob Pieters; Charlotte M Niemeyer; Vincent H J van der Velden
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

10.  Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.

Authors:  Nicolas Goardon; Emmanouil Nikolousis; Alexander Sternberg; Wai-Kit Chu; Charles Craddock; Peter Richardson; Richard Benson; Mark Drayson; Graham Standen; Paresh Vyas; Sylvie Freeman
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.